News

Delstrigo is a once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg). Pifeltro (doravirine, 100mg) is a new non-nucleoside reverse transcriptase

KaNDy is focused on optimizing the potential of NT-814 as a non-hormonal treatment for common, chronic debilitating female sex-hormone associated conditions. The funding came from new US investor

The new facility, which will serve as the flagship location for ICS, will further strengthen the company’s already robust end-to-end, integrated solutions for improving access to specialty medication,

Adapt Pharma is a privately-held company committed to expanding affordable access to Narcan (naloxone HCI) nasal spray and to progressing treatment options in the field of addiction. The

Onvansertib is a first-in-class, third generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor. Trovagene executive chairman Dr Thomas Adams said: “The European Commission’s decision to grant orphan

The study results, as well as the results of Sonoma’s previous HOCl acne studies (total of 127 patients), were presented by the principal investigator, Mark Steven Nestor, M.D.,

Under the terms of the agreement, Purdue will pay Assertio a total of $62 million in cash, with $30 million in cash paid on August 28, 2018 and

As part of the deal, Affimed will authorize its redirected optimized cell killing (ROCK) platform to discover and optimize innate immune cell engager-based immunotherapeutics of interest to Genentech.

Harbour BioMed is engaged in the discovery and development of therapeutics for oncology and immunological diseases. The financing round was led by GIC Private Limited, and participants included